Study of NGM313 in Obese Participants

Phase 1CompletedNCT03298464

NGM Biopharmaceuticals, Inc25 enrolled

Overview

The purpose of the study is to evaulate the safety, tolerability, and efficacy of NGM313 in obese participants

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Obese

Interventions

NGM313BIOLOGICAL

Subcutaneous injection

PioglitazoneDRUG

White to off-white round tablet

Eligibility

Sex: ALLMin age: 21 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Body mass index (BMI) of 30-43 kg/m2 * Waist circumference \> 40 inches in males or \> 30 inches in females * Normal ECG readings Exclusion Criteria: * Significant history or clinical manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder * History of any known Congestive heart failure (CHF) * History of macrovascular disease

Locations (1)

Prosciento

Chula Vista, California, United States

Outcomes

Primary Outcomes

Evaluation of whole body insulin sensitivity measured as insulin sensitivity index (M and Si) following intravenous insulin administration

Time frame: 28 Days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.